Cargando…
The Complex Structure of the Pharmacological Drug–Disease Network
The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466955/ https://www.ncbi.nlm.nih.gov/pubmed/34573762 http://dx.doi.org/10.3390/e23091139 |
_version_ | 1784573273125683200 |
---|---|
author | López-Rodríguez, Irene Reyes-Manzano, Cesár F. Guzmán-Vargas, Ariel Guzmán-Vargas, Lev |
author_facet | López-Rodríguez, Irene Reyes-Manzano, Cesár F. Guzmán-Vargas, Ariel Guzmán-Vargas, Lev |
author_sort | López-Rodríguez, Irene |
collection | PubMed |
description | The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures). |
format | Online Article Text |
id | pubmed-8466955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84669552021-09-27 The Complex Structure of the Pharmacological Drug–Disease Network López-Rodríguez, Irene Reyes-Manzano, Cesár F. Guzmán-Vargas, Ariel Guzmán-Vargas, Lev Entropy (Basel) Article The complexity of drug–disease interactions is a process that has been explained in terms of the need for new drugs and the increasing cost of drug development, among other factors. Over the last years, diverse approaches have been explored to understand drug–disease relationships. Here, we construct a bipartite graph in terms of active ingredients and diseases based on thoroughly classified data from a recognized pharmacological website. We find that the connectivities between drugs (outgoing links) and diseases (incoming links) follow approximately a stretched-exponential function with different fitting parameters; for drugs, it is between exponential and power law functions, while for diseases, the behavior is purely exponential. The network projections, onto either drugs or diseases, reveal that the co-ocurrence of drugs (diseases) in common target diseases (drugs) lead to the appearance of connected components, which varies as the threshold number of common target diseases (drugs) is increased. The corresponding projections built from randomized versions of the original bipartite networks are considered to evaluate the differences. The heterogeneity of association at group level between active ingredients and diseases is evaluated in terms of the Shannon entropy and algorithmic complexity, revealing that higher levels of diversity are present for diseases compared to drugs. Finally, the robustness of the original bipartite network is evaluated in terms of most-connected nodes removal (direct attack) and random removal (random failures). MDPI 2021-08-31 /pmc/articles/PMC8466955/ /pubmed/34573762 http://dx.doi.org/10.3390/e23091139 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article López-Rodríguez, Irene Reyes-Manzano, Cesár F. Guzmán-Vargas, Ariel Guzmán-Vargas, Lev The Complex Structure of the Pharmacological Drug–Disease Network |
title | The Complex Structure of the Pharmacological Drug–Disease Network |
title_full | The Complex Structure of the Pharmacological Drug–Disease Network |
title_fullStr | The Complex Structure of the Pharmacological Drug–Disease Network |
title_full_unstemmed | The Complex Structure of the Pharmacological Drug–Disease Network |
title_short | The Complex Structure of the Pharmacological Drug–Disease Network |
title_sort | complex structure of the pharmacological drug–disease network |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466955/ https://www.ncbi.nlm.nih.gov/pubmed/34573762 http://dx.doi.org/10.3390/e23091139 |
work_keys_str_mv | AT lopezrodriguezirene thecomplexstructureofthepharmacologicaldrugdiseasenetwork AT reyesmanzanocesarf thecomplexstructureofthepharmacologicaldrugdiseasenetwork AT guzmanvargasariel thecomplexstructureofthepharmacologicaldrugdiseasenetwork AT guzmanvargaslev thecomplexstructureofthepharmacologicaldrugdiseasenetwork AT lopezrodriguezirene complexstructureofthepharmacologicaldrugdiseasenetwork AT reyesmanzanocesarf complexstructureofthepharmacologicaldrugdiseasenetwork AT guzmanvargasariel complexstructureofthepharmacologicaldrugdiseasenetwork AT guzmanvargaslev complexstructureofthepharmacologicaldrugdiseasenetwork |